Müskens Wieland D, Rongen-van Dartel Sanne A A, Adang Eddy M M, van Riel Piet L C M
Department of IQ Healthcare, Radboudumc, Nijmegen, The Netherlands.
Department of Rheumatology, Bernhoven, Uden, The Netherlands.
Mediterr J Rheumatol. 2019 May 31;30(Suppl 1):76-81. doi: 10.31138/mjr.30.1.76. eCollection 2019 Jun.
These days, the use of biosimilars for the treatment of bio-naive patients is well established. However, the transition of patients being treated with a bio-originator to its biosimilar is still a topic of discussion. The main issue is which approach to use when initiating the non-medical transition. The first real-world examples contain both mandatory and non-mandatory approaches, resulting in a variety of acceptance and discontinuation rates. At this moment a non-mandatory approach, based on shared decision making, is preferred by international guidelines and the Task Force on the Use of Biosimilars to Treat Rheumatological Diseases. However, clear definitions of mandatory and non-mandatory are lacking, as a result of which these terms may be wrongly used in some studies. This article aims to provide an overview of transition approaches used in the Netherlands, and how the approach used relates to acceptance and discontinuation rates of the biosimilar.
如今，生物类似药用于初治患者的治疗已得到充分确立。然而，正在接受原研生物药治疗的患者向其生物类似药的转换仍是一个讨论话题。主要问题是在启动非医疗转换时采用哪种方法。首批真实世界案例包含强制性和非强制性方法，导致了各种接受率和停药率。目前，基于共同决策的非强制性方法受到国际指南以及生物类似药治疗风湿性疾病工作组的青睐。然而，缺乏对强制性和非强制性的明确定义，因此这些术语在一些研究中可能被错误使用。本文旨在概述荷兰使用的转换方法，以及所采用的方法与生物类似药的接受率和停药率之间的关系。
